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 Abstract 
 
Given the challenges associated with collection of tumor specimens for biomarker 
monitoring, collection of surrogate tissues (e.g., normal tissues such as hair or blood) 
may enable the assessment of pharmacodynamic (PD) biomarkers. For chemotherapeutic 
agents, limited work has been done to establish pharmacodynamic (PD) biomarkers in 
these surrogate specimens. This study aims to demonstrate that surrogate specimens, 
specifically hair follicles and whole blood, are a viable option for assessment of PD 
biomarkers in response to chemotherapy in the clinic.  
Traditional chemotherapeutic agents act by targeting rapidly dividing cells, one of 
the hallmarks of most cancers and some normal cells such as bone marrow, hair follicles 
and cells that line the digestive tract.  Many chemotherapeutic agents, such as 
anthracyclines, topoisomerase inhibitors, and alkylating agents (e.g., platinums), work by 
directly damaging a cell’s DNA in some or all phases of the cell cycle. The mechanism 
by which DNA damaging agents target erroneously dividing cells is indiscriminant and 
therefore results in DNA damage-induction in rapidly dividing healthy cells. The desire 
to better understand the biological reasons why cancer arises, propagates, and 
metastasizes, combined with a wider acceptance of personalized medicine, has led to the 
 development of targeted therapies.  However, despite, the development of multiple anti-
cancer targeted agents, chemotherapy remains the mainstay of cancer therapeutics.  As 
such, there is a need to further develop biomarkers that aid in our understanding of 
chemotherapeutic activity.  
In order to study these specimens, consent was obtained from healthy volunteers 
for the collection of hair follicles and whole blood, treated ex vivo, and evaluated by 
immunohistochemistry and flow cytometry for biomarkers of DNA damage. As an 
expansion of the whole blood work, blood was also obtained from rats after in vivo 
exposure to various DNA damaging agents.  
This study demonstrates that human hair follicles are a viable option for 
biomarker monitoring in oncology. Specifically, gH2AX can be used as a DNA damage 
marker. To enable robust assessment of DNA damage markers in surrogate specimens, 
multiple biological replicate must be collected given the expected variability in data 
generated. Results from this study also indicate that human whole blood will need more 
investigation before it is used clinically. Detection in whole blood was unsuccessful after 
ex vivo stimulation but in vivo exploration in rats yielded positive data.  
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Chapter I 
Introduction 
 
 
One of the largest unmet medical needs in developed countries is the treatment of 
cancers. Cancer is a group of diseases characterized by the uncontrolled growth and 
spread of abnormal cells (Cancer Facts and Figures, 2014).  Specifically, cancer cells 
have the ability to evade apoptosis, are self-sufficient in growth, are insensitive to anti-
growth signals, metastasize and invade healthy tissues, have limitless replicative potential 
and promote angiogenesis (Hanahan et al., 2000). Over 1.6 million new cancer diagnoses 
are expected to occur in 2015, half a million of which are expected to be terminal 
diagnoses (Cancer Facts and Figures, 2014).  Thus, cancer in general, illustrates a clear 
unmet medical need with much room for improvement in terms of treatments and 
therapies.  
 
Standard of Care Therapies for the Treatment of Cancer 
 
Surgery and radiation therapy dominated the cancer therapy space until the 1960s 
when the cure rates began to plateau at about 33% (DeVita, 2008). Chemotherapy agents, 
classified as a cancer treatment that uses chemical substances, were introduced shortly 
thereafter in the 1970’s when adjuvant chemotherapy was shown to cure patients with 
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various advanced cancers. In adjuvant therapy, the chemotherapy is applied after the 
radiation and surgery to maximize effectiveness and ultimately suppress tumor formation. 
Adjuvant chemotherapy allowed physicians to target the cancerous cells leftover from 
surgery and radiation, thus leading to reduced metastases and significant improvements in 
efficacy. Since then, chemotherapy, which can be used as the primary therapeutic or in 
conjunction with surgery and radiation, has become the standard of care (SOC) for the 
treatment of a many tumor types (e.g., breast cancer, non-small cell lung cancer, pancreas 
cancer, ovarian cancer, etc).  
Chemotherapy can be subdivided into several different classes based on the 
mechanism of action.  Chemotherapy induces various types of DNA damage including 
modification of nucleotide bases, intrastrand crosslinks, interstrand crosslinks, DNA-
protein crosslinks, single-strand breaks (SSBs), and double-strand breaks (DSBs). 
However, different chemotherapeutic agents have distinct mechanism of actions (MOAs). 
For the purposes of this study, we will focus on three classes of DNA damaging agents: 
alkylating agents (e.g., platinums), topoisomerase II inhibitors (e.g., etoposide and 
doxorubicin), and topoisomerase I inhibitors (e.g., irinotecan).  
The chemotherapy drug carboplatin is classified as a platinum-based alkylating 
agent that is typically used to treat a wide range of cancers, most notably ovarian cancer. 
DNA alkylation causes DNA crosslinking and eventual single strand breaks (SSBs). This 
interferes with a cell’s ability to repair DNA and/or create new DNA via replication. 
Interference with the cell’s DNA repair machinery ultimately leads to cell death.  
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Another chemotherapeutic drug, etopiside, works in a different way by blocking 
the action of an enzyme called topoisomerase II. Etoposide is used to treat a wide range 
of different cancer types including testicular, bladder, prostate,lung, stomach and uterine 
cancers. Type II topoisomerase is responsible for cutting the strands of DNA, promoting 
chromosome disentanglement before strand separation during DNA replication. Blocking 
this enzyme leads to both single and double strand breaks in the DNA (SSBs, DSBs), and 
eventual cell death. Doxil is another topoisomerase II inhibitor that will be explored in 
this work.  
Another mode of DNA damage is to target an enzyme called topoisomerase I. 
Chemotherapeutic agent, irinotecan, is a topoisomerase I inhibitor and is typically used to 
treat people with colon or rectal cancer. Similar to topoisomerase II, the topoisomerase I 
enzyme is responsible for breaking single-strand DNA to relax and reanneal the DNA 
strand. Inhibition of topoisomerase I causes both single (SSBs) and double strand (DSBs) 
breaks in the DNA, leading to cell death.  
Since these chemotherapeutic drugs cannot distinguish between cancerous and 
non-cancerous cells, a fair amount of normal cell death occurs. This leads to undesirable 
side effects and toxicities in patients such as nausea, vomiting, hair loss, and diarrhea. 
However, chemotherapy works best on cells that are rapidly dividing which is a key 
characteristic of a cancer cell, making them more likely to be affected by 
chemotherapeutic agents. This ultimately allows for successful treatment outcomes albeit 
the undesired side effects.  
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Targeted Cancer Therapies 
 
Standard of care (SOC) chemotherapy agents that are designed to kill cancer cells 
by inducing DNA damage are oftentimes coupled with specific, targeted, cancer 
therapies. This can lead to increased efficacy as the DNA damage, induced by the 
chemotherapeutic agent, is recognized and processed by proteins involved in the DNA 
damage response (DDR) such as PARP-1, DNA-PK, XRCC1, etc.  Using targeted 
therapies to inhibit the DDR may enhance the therapeutic effect when combined with 
DNA-damaging agents (Hosoya, 2014). Preclinical studies have shown that combining 
PARP1 inhibitors with, for example, platinum chemotherapy agents, which induce DNA 
damage through adducts and cross linking, potentiates chemotherapeutic cytotoxicity, 
leading to better efficacy (Alli, 2009).  
Careful monitoring of the PD effect of a targeted agent such as a PARP inhibitor 
requires an understanding of the PD effect in response to the chemotherapeutic alone.  
This will enable an understanding as to whether biomarker changes are due to the SOC 
treatment or targeted therapy. Understanding how DDR biomarkers change in response to 
DNA damaging agents may help inform the selection of a biologically active dose and/or 
dose schedule of combined therapies such as chemotherapy in combination with a PARP 
inhibitor. This study will aim to characterize the baseline pharmacodynamic biomarker 
effect DNA damaging agents before combination with targeted agents.   
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Biomarker Monitoring in Oncology 
 
One commonly used definition of a biomarker is a measurable indicator that is 
used to precisely, reproducibly and objectively distinguish either a normal biological state 
from a pathological state, or the response to a specific therapeutic intervention (Gramont, 
2014). Biomarker monitoring in the oncology setting is essential to gain a complete 
understanding of why a particular treatment may or may not be successful in the clinic. 
Within the broad field of oncology, there are hundreds of different types of cancers each 
with its own etiology, prognosis and course of treatment.  In the development of most 
drugs in the oncology space two types of biomarkers tend to be utilized: 
1) Patient selection markers 
2) Target engagement/pharmacodynamics markers 
 Identification of patient selection markers is particularly important in cancer 
therapy given the heterogeneity of disease even among patients with the same diagnosis 
or cancer type. Patient selection biomarkers may begin to pull apart this heterogeneity 
and identify and treat subsets of patients that are predicted, based on their specific 
molecular defects and aspects of tumor microenvironment, to respond to a particular 
therapy (Kelloff, 2012). There are numerous well-known examples of targeted drugs and 
their respective biomarkers. For example, vemurafenib - a BRAF kinase inhibitor - has 
been approved for the treatment of metastatic melanoma patients who have the 
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BRAF
V600E
 mutation in their tumors. Patients that do not contain the BRAF
V600E 
mutation, are not predicted to respond to vemurafenib based on the MOA of the therapy 
and thus should not be treated or included in later phase clinical trials where you want to 
demonstrate clinical efficacy, but biomarker monitoring does not stop with this.  
With an emphasis on molecularly targeted strategies, biomarkers that are 
indicative of a drugs pharmacodynamic mechanism of action or illustrative of target 
engagement are essential. Target engagement biomarkers can be proximal or distal, 
where the proximal biomarker is a direct target engagement readout and may even be 
evidence of a direct substrate of the target. For kinase drugs, for example, protein 
substrate phosphorylation represent candidate proximal target engagement biomarkers. 
However, substrate phosphorylation is oftentimes controlled by input from multiple 
converging pathways, complicating assessment of target engagement of a small molecule 
(Paweletz, 2011). Thus, careful consideration and validation is needed when identifying 
candidate target engagement biomarkers as biomarker changes should be specific to 
modulation of the target of interest due to drug treatment. Distal target engagement 
biomarkers are generally located downstream of the target, are disease-related and are 
often referred to as outcome or pharmacodynamic biomarkers.  
Pharmacodynamic (PD) biomarkers are modulated over time in response to a 
therapy and measure near-term treatment effects of a drug on the tumor or person 
(Sawyers, 2008). While pharmacokinetic (PK) measurements of drug concentrations in 
plasma are routine, establishing a relationship between the pharmacodynamic biomarker 
and pharmacokinetic profile provides a much deeper understanding of what is going on in 
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the patient after treatment with drug. Preclinical PK/PD profiling in xenograft models 
allows one to model the relationship between systemic drug exposure and biomarker 
changes associated with anti-tumor activity. This provides a benchmark for target PK 
exposures in the clinic as well as biomarker levels expected to render a clinically 
meaningful result (Takimoto, 2009). Furthermore, pharmacodynamic monitoring in the 
clinic can allow one to adjust dose and schedule based on the modulation of the PD 
biomarker to achieve the greatest coverage of target and ultimately efficacy. 
Pharmacodynamic monitoring is complicated, however, by the combination treatment 
regimens oftentimes used in the oncology setting. Since combination therapy obscures 
the association between any one agent used in the treatment regimen and the biomarkers 
under consideration, it is important to understand the baseline response of certain 
biomarkers to SOC agents in order to fully appreciate modulation of the biomarker after 
treatment (Gramont, 2014).  
 
Biomarkers of DNA damage 
 
 To ensure successful duplication and transmission of genetic material, the cell has 
evolved the ability to detect DNA damage which causes a variety of cellular responses 
including cell cycle arrest, DNA repair, senescence and apoptosis. Collectively, these 
processes are referred to as the DNA damage response (DDR). Damage, in the form of 
single strand or double strand DNA lesions, trigger activation of various kinases, most 
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importantly the phosphoinositide-3-kinase-related protein kinase (PI3K) family made up 
of ATM, ATR and DNA-PKcs.  
When considering the frequency at which primary and adjuvant chemotherapy 
regimens are utilized, the majority of cancers at one point or another are treated with 
chemotherapy. There are a number of markers one could monitor in response to the DNA 
damage caused by chemotherapeutic agents. For purposes of this study, we will focus on 
three specific markers of DNA damage response: gH2AX, pChk1, and pKAP1.  
 Double strand breaks (DSBs) are considered to be the most lethal forms of DNA 
damage since it prevents the cell from carrying out DNA replication. As such they must 
be identified and repaired quickly. As an early cellular response to DSBs, H2AX is 
phosphorylated at Ser-139 to produce γH2AX. This phosphorylation event is now one of 
the most well-established chromatin modifications linked to DNA damage and repair 
(Mah, 2010). Phosphorylation of H2AX modulates DNA repair in three ways. First, 
γH2AX facilitates DSB rejoining by anchoring the broken ends together through 
nucleosome repositioning. γH2AX then recruits cohesin molecules that are protein 
complexes that regulate the separation of sister chromatids during cell division. The 
cohesins keeps the ends of the DNA strand in close proximity during repair, preventing 
large loss of chromosomal regions. Finally, γH2AX modulates checkpoint responses, 
giving DNA time to repair (Mah, 2010). Thus, γH2AX becomes a ubiquitous marker for 
DNA damage.  
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 Ataxia telangiectasia and Rad3-related protein (ATR), one of the PI3K family 
proteins involved in the DNA damage response pathway, is activated upon recognition of 
DNA structures that are induced by DNA damage, such as single-stranded DNA 
(ssDNA) and junctions between ssDNA and double-stranded DNA (dsDNA) (Shiotani,  
2009). In response to DNA damage, activated ATR phosphorylates Chk1 at Ser-345 
which activates a cascade of DNA damage repair. Specifically, activation of Chk1 by 
phosphorylation arrests cells at the G2 phase of the cell cycle in response to DNA 
damage. As cells are damaged, pChk1 accumulates as an s-phase biomarker of cell 
synchrony in response to DNA damaging agents.  Thus, pChk1 can be used to measure 
DNA damage caused by single strand breaks in the DNA.  
 PI3K family protein, ataxia telangiectasia mutated (ATM), becomes activated in 
response to DNA damage, specifically double strand DNA (dsDNA) breaks. KAP1 is a 
hererochromatin protein that is robustly phosphorylated by ATRM at Ser-824 in response 
to DNA damage and ATM activation. Therefore, pKAP1 can be used as a marker of 
DNA damage caused by double strand breaks in the DNA.  
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Table 1.  Types of DNA damaging agents, the type of damage induced and biomarkers 
used for monitoring. 
DNA 
Damaging 
agent 
Category of DNA 
Damaging Agent 
Type of Damage Induced 
Biomarker for 
Monitoring 
Carboplatin Alkylating agent 
Single-strand breaks in 
DNA (DSBs) 
gH2AX; pChk1 
Etoposide / 
Doxorubicin 
Topoisomerase II 
inhibitor 
Double-strand breaks in 
DNA (DSBs) 
gH2AX; pKAP1 
Single-strand breaks in 
DNA (SSBs) 
pChk1 
Irinotecan 
Topoisomerase I 
inhibitor 
Double-strand breaks in 
DNA (DSBs) 
gH2AX; pKAP1 
Single-strand breaks in 
DNA (SSBs) 
pChk1 
 
 
Tumor tissues for biomarker monitoring 
 
 Pharmacodynamic evaluation of targeted drugs using tumor biopsies obtained 
before and after drug exposure is usually performed in oncology trials to confirm that 
drug-induced biological effects achievable in preclinical models can also be observed in 
vivo (Ma, 2006). These effects may include modulation of a proximal target engagement 
marker, or pathway modulation of distal pharmacodymic biomarkers. In a Phase II study 
using gefitinib, an orally active EGFR tyrosine kinase inhibitor used in patients with non-
small-cell lung cancer (NSCLC), investigators aimed to determine antitumor activity of 
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gefitinib using sequential tumor biopsies obtained from patients on drug. Specifically, 
their goal was to study the effects of gefininib in patients with advanced gastric cancer on 
EGFR phosphorylation and on the two major receptor signaling pathways - MAPK and 
PI3K/Akt, as well as its effect on proliferation and apoptosis (Rojo, 2006). Tumor 
biopsies were obtained at screening, prior to gefitinib treatment, on day 28 of treatment, 
and, if possible, at disease progression. Of the 70 patients enrolled on the study, only 32 
(45.7%) had evaluable sequential paired biopsies prior to and post-gefitinib treatment. 
This speaks to the difficulty in procuring such an invasive specimen for research 
purposed only.   This study highlights one of the challenges associated with collection of 
biopsies in clinical trials.  
Analysis of these collected specimens becomes difficult as well when considering 
the heterogeneity of a tumor specimen. When considering analyzing the timed tumor 
biopsy specimen via an imunohistorchemical (IHC) assay to assess a particular biomarker 
intratumorally, heterogeneity plays a major role in the likelihood of obtaining a 
meaningful result, especially when tumor material is so limited.  
There are many additional challenges to successful incorporation of tumor tissue 
acquisition and analysis into clinical trial execution. For instance, a patient’s malignancy 
and location of the proposed tumor biopsy play a significant role in the success of 
procuring the specimen. In a retrospective conducted by the NIH, six phase 1/2 clinical 
studies were evaluated to understand the optional target tissue for safe research in tumor 
biopsies. Of the 142 patients that consented to research biopsies, 109 (77%) of them were 
ovarian cancer patients. By contrast, adrenal, mesothelioma, renal cell carcinoma and 
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thyroid cancer combined made up only 3% of the specimens analyzed (Lee, 2013). Thus, 
there is no doubt location and tumor type play a role in the likelihood of procuring these 
specimens.  
In addition, there is risk of complication due to biopsy. For example, there is 
some concern around the “seeding” of tumor cells following biopsies. As the needle 
transgresses the tumor field and is withdrawn, there is potential for cells located in the 
tumor to migrate into the adjacent soft tissue and skin as a consequence of the violation 
of the tissue by the biopsy needle (Loughran, 2011). Furthermore, in a study that assessed 
a total of 57 clinical trials, biopsy-related complications were observed in 5.2% (39 of 
745 biopsies) (Overman, 2013).  Complications were related to the location of the biopsy, 
with the highest complication rate being for intrathoracic biopsies at 17.1% (Overman, 
2013).  
Complications due to biopsy and general inconvenience may lead to decreased 
consent to optional research assessments. This may make biomarker monitoring in the 
clinic difficult if target engagement or pharmacodynamic effect cannot be confirmed. 
Thus, there needs to be alternative ways to monitor disease effect via biomarker sin the 
clinic besides assaying the actual tumor repeatedly.  
 
 13 
Surrogate tissues for biomarker monitoring 
 
 While tumor biopsies are considered to be the gold standard for assessing 
molecular changes in tissue to guide drug development in oncology, there is an increasing 
uptake of the use of normal “surrogate” tissues into clinical trials. Biomarker profiling in 
surrogate tissues, such as blood or hair follicles, offer many advantages over the invasive 
sampling of tumor tissue. For example, collections of surrogate tissues incur low 
procedural risk, as collections are far less invasive. As such, there is a high likelihood a 
patient will consent to the sampling leading to increased compliance and a more complete 
understanding of the markers evaluated in the surrogate specimens.  
Furthermore, surrogate specimens are amenable to repeat sampling in a way 
tumor biopsies generally are not. Instead of only taking a pre- and post-treatment sample, 
surrogate specimens can be sampled many times over a period of time. This allows for 
full characterization of pharmacodynamic changes that occur in response to drug 
treatment.  
 PBMCs or peripheral blood mononuclear cells are the populations of immune 
cells that are oftentimes extracted from a whole blood sample to perform biomarker 
analyses on. PBMCs include lymphocytes, monocytes and dendritic cells and are 
characterized as having a round nucleus. As such, they can be used to monitor gene 
expression in whole blood, making them amenable to biomarker monitoring. During 
development of a first-in-class hsp90 inhibitor, the correlation between pharamodynamic 
changes in PBMCs and in tumor tissue was established in vivo models. Following this, in 
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the PK/PD driven Phase I study tumor biopsies were performed only after the satisfactory 
demonstration of plasma concentrations above those required for activity in human tumor 
xenograft models and evidence of pharmacodynamic modulation in PBMCs (Ang, 2012). 
PBMCs were also used to develop a PK/PD model for Everolimus, an mTOR inhibitor 
that was recently approved by the FDA and EMA. Everolimus has been demonstrated to 
inhibit the phosphorylation and activity of the downstream mTOR-regulated SK6 in vitro, 
in vivo in tumors as well as in surrogate tissues in both rats and mice (O’Reilly, 2010). 
As a result, detection of S6K1 activity in human PBMCs was used to evaluate everolimus 
dosing schedules. Specifically, S6K1 activity was monitored in PBMCs derived from 
healthy human volunteers after ex vivo treatment with 2nM everolumus for 30 minutes 
leading to 44% and 63% inhibition in two different donors (O’Reilly, 2010). Exploration 
of dose and schedule using PK/PD modeling in human PBMCs allows for exploration of 
a sufficient drug level to inhibit a biological endpoint to provide an optimal biologic 
dose. These two studies, among others, demonstrate the utility of PBMCs in the 
biomarker space.   
 Hair follicles offer another attractive surrogate specimen that is sometimes used in 
pharmacodynamic biomarker monitoring in the clinic as evidence of the mode of action 
of the drug on human tissues via the proposed pathway. Plucked human hairs contain 
proliferating cells within the hair sheath making them attractive as an easily accessible 
tissue in which to assess the pharamacodynamic effects of drugs that interfere with cell 
proliferation, such as chemotherapeutic agents (Camidge, 2005). In addition, hair follicles 
are highly vascularized, making them susceptible to similar drug exposures seen in the 
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plasma. Methods for the fixation, processing, sectioning and immunohistochemical (IHC) 
staining of a number of oncology-relevant antibodies on plucked hair has been previously 
described and summarized by Randall, et al. (2007). Similar methods have been utilized 
in hair follicles by Yap, et al. (2010) to develop novel biomarker assays for the inhibition 
of AKT in human hair follicles in the clinic. Specifically, phosphorylation and total 
protein expression of the AKT substrate PRAS40 was measured in hair follicles. 
Significant decreases in pThr246 PRAS40 was demonstrated in AKTi treated mouse 
whisker follicles in vivo and human hair follicles treated ex vivo, with minimal changes in 
total PRAS40 (Yap, 2010).  
 Given the above considerations in surrogate tissues, we propose ex vivo 
evaluation of surrogate specimens for tumor tissue that can be used to perform biomarker 
analyses, specifically in hair follicles and peripheral blood mononuclear cells (PBMCs). 
By studying DNA damage biomarkers in surrogate tissues, such as hair follicles and 
blood, it will help us understand how these surrogate tissue specimens respond to 
traditional DNA damaging agents and whether or not they can be used for biomarker 
monitoring in the clinic. 
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Chapter II 
Materials and Methods 
 
 
A variety of methods were employed during this research to examine biomarkers 
of DNA damage in human hair follicles and human whole blood. In order to study these 
specimens, consent was obtained from healthy volunteers for the collection of hair 
follicles and whole blood as described below and treated ex vivo. As an expansion of the 
whole blood work, blood was also obtained from rats after in vivo exposure to various 
DNA damaging agents. Both immunohistochemisty and flow cytometry were utilized to 
examine the prepared specimens. Methods described in more detail as follows.  
 
Biospecimen Collection 
 
Human scalp hairs were plucked with tweezers from the side of the head and 
visually checked for the presence of an anagen hair bulb (growth phase). The hair bulbs 
were then transferred to either 10% buffered formalin for immediate fixation, cell culture 
media (proprietary, provided by Epistem LTD.), or cell culture media supplemented 
DNA damaging agents (e.g. Cisplatin, Etoposide, Irinotecan (SN38)). A total of 5 anagen 
hair follicles were collected per treatment group and cultured for 17, 24, or 28 hours, 
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excluding the hairs that were uncultured and fixed immediately. Specific culture 
conditions and processing described below. 
Human whole blood was collected intravenously into 10mL sodium heparin 
(NaHep) Vacutainer® tubes (BD, Catalog number: 366480) and stored at room 
temperature overnight before processing. Blood was aliquoted and treated with DNA 
damaging agents (e.g. Carboplatin, Etoposide, Irinotecan (SN38)) for 1, 4, and 8 hours. 
Specific treatment conditions described below.      
Whole blood from rats treated with Etoposide was collected at 1, 2, 7 and 24 
hours post dose. Specifically, rats were cannulated in jugular vein and blood collection 
was from cannula. Blood was immediately lysed and fixed.  
 
DNA Damage Induction in Hair 
 
To assess known DNA damage markers in hair follicles, hair follicles were 
collected from three healthy male donors and immediately transferred to ex vivo culture 
conditions according to Table 2 below.   
 
 
 
 18 
Table 2.  Experimental groups to assess known DNA damage markers in hair follicles.  
 
Experimental 
Group 
Treatment 
Harvest 
time 
Number 
of hairs / 
donor 
Number 
of 
Sections 
analyzed / 
hair 
DNA damage 
maker 
analyzed 
1 
NA-
Uncultured 
fresh 
plucked 
hairs 
Fixed 
Immediately 
5 3 
γ-H2AX, 
pChk1 
2 Untreated 24 hours 5 3 
γ-H2AX, 
pChk1 
3 
Vehicle 
(0.1% 
DMSO) 
24 hours 5 3 
γ-H2AX, 
pChk1 
4 
50µM 
Carboplatin 
24 hours 5 3 
γ-H2AX, 
pChk1 
5 
10µM 
Etoposide 
24 hours 5 3 
γ-H2AX, 
pChk1 
6 
100nM 
Etoposide 
24 hours 5 3 
γ-H2AX, 
pChk1 
 
 
To assess the dynamics of DNA damage in hair, hair follicles were collected from 
three healthy male donors and immediately transferred to an ex vivo culture and 
harvested at multiple timepoints according to Table 3 below.  
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Table 3.  Experimental groups to assess biomarker dynamics at multiple timepoints.  
 
Experimental 
Group 
Treatment 
Harvest 
time 
Number 
of hairs / 
donor 
Number of 
Sections 
analyzed / 
hair 
DNA 
damage 
maker 
analyzed 
1 
NA-
Uncultured 
fresh 
plucked 
hairs 
Fixed 
Immediately 
5 3 γ-H2AX 
5 4 pChk1 
2 Untreated 
17, 24, 28 
hours 
5 3 γ-H2AX 
5 4 pChk1 
3 
Vehicle 
(0.1% 
DMSO) 
17, 24, 28 
hours 
5 3 γ-H2AX 
5 4 pChk1 
4 
50µM 
Carboplatin 
17, 24, 28 
hours 
5 3 γ-H2AX 
5 4 pChk1 
5 
10µM 
Etoposide 
17, 24, 28 
hours 
5 3 γ-H2AX 
5 4 pChk1 
6 
100nM 
Etoposide 
17, 24, 28 
hours 
5 3 γ-H2AX 
5 4 pChk1 
 
 
Hair follicles were cultured in cell culture media (provided by Epistem LTD., 
proprietary) or cell culture media supplemented with Carboplatin (Sigma, Catalog 
number: C2538), Etoposide (Sigma, Catalog number: E1383), or SN38, the active 
metabolite of Irinotecan (Santa Cruz, Catalog number: sc-203697) according to Table 2 
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and Table 3. Specifically, Carboplatin was prepared as a 50mM stock solution in DMSO 
by dissolving 100mg of Carboplatin into 5.387mL DMSO. The stock was then further 
diluted 1:1000 into proprietary cell culture media producing final working concentration 
of 50uM (0.1% DMSO volume).  
Etoposide was prepared as a 20mM stock solution in DMSO by dissolving 
58.856mg of Etoposide into 5mL DMSO. The stock was then further diluted 1:2000 into 
proprietary cell culture media producing a final working concentration of 10uM (0.05% 
DMSO volume).  
SN38, which is the active metabolite of Irinotecan, was prepared as a 200uM 
stock solution in DMSO by dissolving 10mg of SN38 into 25.486mL DMSO (1mM 
stock) and then a further serial dilution (1:5) again into DMSO. The 200uM stock was 
finally diluted 1:2000 into proprietary cell culture media producing a final working 
concentration of 100nM (0.05% DMSO volume).  
All concentrations of DNA damaging agents were chosen as they were shown to 
kill a large number of cancer cells in in vitro experiments (data not shown) and were 
determined to be the IC90 concentrations in the particular assays utilized.  
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Processing of Plucked Human Hairs 
 
 After culture, or immediately upon collection, hairs were fixed in 10% buffered 
formalin for 30 minutes and transferred to 70% ethanol for up to a week for paraffin 
embedding (one hair per paraffin block). Ten longitudinal 3uM thick sections were cut 
per block per donor per experimental group. Sections were mounted onto charged slides 
and individual sections were stained for γ-H2AX and pChk1 and analyzed by IHC.       
 
Immunohistochemistry 
 
 Slides containing hair sections were de-waxed in xylene and rehydrated through 
graded alcohols to PBS. Endogenous peroxidase was blocked with 0.3% H2O2 in PBS 
before rinsing in PBS. Non-specific binding was blocked with 10% normal goat serum in 
TBST for 30 minutes.  
After removing blocking serum, the sections were incubated with a rabbit 
polyclonal anti-γ-H2AX antibody  (Bethyl Laboratories, Catalog number: IHC-00059) at 
a dilution of 1:250 in TBST containing 5% normal goat serum and incubated for 1 hour at 
room temperature. Sections were then rinsed with TBST and detection of primary 
antibody was carried out by using a biotinylated goat-anti-rabbit secondary antibody 
(Vector Lab Inc, diluted 1:200 for 30 minutes) followed by incubation for 30 minutes 
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with Vector ABC Elite reagents (Vector Lab Inc.; peroxidase-labeled avidin-biotin 
complex).  
  To evaluate pChk1 staining, sections underwent antigen retrieval by 
microwaving for 20 minutes in pH6 citrate buffer before blocking endogenous peroxidase 
using 3% H2O2 in RO water for 10 minutes. Non-specific binding was blocked using 5% 
normal goat serum in PBST for 20 minutes. Sections were then incubated with rabbit 
monoclonal anti-pChk1(ser345) antibody (Cell Signaling, Catalog number: 2348) diluted 
1:50 in PBST for 1 hour at room temperature. Sections were subsequently rinsed in PBST 
and detection of the primary antibody was completed using biotinylated goat-anti-rabbit 
secondary antibody (Vector Lab Inc, diluted 1:200 for 30 minutes). This was rinsed in 
PBST and all slides were treated for 30 minutes using Vector ABC Elite reagents (Vector 
Lab Inc.; peroxidase-labeled avidin-biotin complex).  
 For both gH2AX and pChk1 staining, primary antibody was removed and 
substituted with TBST as a negative control. Within each labeling run, two slides of skin 
biopsies (+/- UVB induced DNA damage) was used as a positive and negative controls, 
respectively. Labeling was visualized with ImmPAT DAB perosidise substrate (Vector 
Lab Inc). All sections were finally coutnterstained using Garvey’s haematoxylin and 
dehydrated through to xylene.  
Skin tissues were treated with 0.485 J/cm
2
 UVB irradiation to be used as a 
positive control for induction of both gH2AX. OD26749 xenograft tumor tissues treated 
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with 3mpk Cisplatin were used as positive controls for pChk1 labeling after induction of 
pChk1 was confirmed via western blot.  
 
Quantification of Labeling in Plucked Hair Sections 
 
 Stained hair sections were scanned using the Aperio® image analysis platform 
and the epithelial outer root sheath (ORS) regions were selected for analysis. Thresholds 
were manually calibrated to group positive cells into distinct labeling intensity groupings. 
Specifically, for gH2AX labeling, 1+ or weak staining was identified as staining with 
thresholds between 195 and 181. 2+ or moderate staining was identified as staining with 
thresholds between 180 and 151. 3+ or strong staining was identified as staining with 
thresholds 150 to 0. Due to the small number of pChk1 positive cells and lack of strong 
intensity variation, all positive cells for pChk1 were identified as staining with thresholds 
from 206 to 0.  
 
DNA Damage Induction in Blood 
 
Human whole blood was aliquoted, in duplicate, into two 15mL conicals and 
treated with compound at varying concentrations to give a total volume of 100ul. 
Specifically, Carboplatin (Sigma, Catalog number: C2538) was prepared as a 50mM 
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stock by dissolving 100mg Carboplatin into 5.38mL DMSO. The 50mM stock solution 
was diluted 1:100 in PBS to create a 500uM working stock. The 500uM working stock 
was finally diluted 1:10 in whole blood producing a final working concentration of 50uM 
(0.1% DMSO).  
Etoposide was prepared as a 50nM stock by dissolving 100mg Etoposide (Sigma, 
Catalog number: E1383) into 3.4mL DMSO. A 1:400 dilution in DMSO followed by a 
1:100 dilution in PBS resulted in a 100uM working stock. The 100uM working stock was 
finally diluted 1:10 in whole blood producing a final working concentration of 10uM 
(0.1% DMSO).  
SN38, the active metabolite of Irinotecan, (Santa Cruz, Catalog number: sc-
203697) was prepared as a 10mM stock by dissolving 10mg SN38 into 2.55mL DMSO. 
A working stock of 1uM was created by diluting the 10mM stock in DMSO by four 1:10 
serial dilutions in DMSO where the last dilution was in PBS. The 1uM working stock 
was finally diluted 1:10 in whole blood producing a final working concentration of 
100nM (0.1% DMSO).  
After the blood was treated with compound, tubes were shaken to ensure mixing 
and placed in a 37°C 5% CO2 incubator for 1, 4, and 8 hours. As a positive control, 
additional aliquots of blood were placed into a γ-particle irradiator and received 2 Gy of 
radiation from a cesium-137 source and were placed in a 37°C 5% CO2 incubator for 1, 4, 
and 8 hours.  
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After the treatment duration, 50X volume of Phosflow
TM
 (1X concentration, 
warmed to 37°C) (BD, Catalog Number: 554656) was added to the blood samples to 
lyse/fix the samples. Samples were inverted 8-10 times to ensure mixing and incubated at 
room temperature for 10 minutes to ensure complete cellular lysis. Tubes were spun at 
200 x g for 10 minutes and supernatant was discarded. 200ul PBS was added to each 
pellet and samples were pipetted up and down to ensure mixing. Samples were 
transferred to a 96-well v-bottom plate and plates were spun at 2000rpm for 5 minutes. 
Supernatant was removed and 200uL ice cold 90% methanol was added and pipetted up 
and down to ensure mixing. Plates were covered with a plate cover and allowed to 
permeabilize overnight at -20°C.  
After permeabilization, samples were pipetted up and down to ensure mixing and 
100ul of each sample was transferred to a new plate and the remaining material was 
stored at -80°C. Plates were spun at 2000rpm for 5 minutes and the supernatant was 
removed. 20ul staining master mix containing 5ul gH2AX antibody (BD Biosciences, 
anti-H2AX (pS139), Alexa Fluor 647, Clone: N1-431, Catalog # 560447), 0.5ul pKAP 
antibody (Pierce, Phospho-TIF1beta, pSer824 Ab DyLight 488, Lot #PL212965), and 
14.5ul PBS-0.5% BSA was added to each sample and was incubated at room temperature 
for 1 hour, on a plate shaker. 200ul PBS + 0.5% BSA was added to each sample and the 
plates were spun at 2000rpm for 5 minutes. Supernatant was discarded. Samples were 
resuspended in 100ul PBS + 0.5% BSA and evaluated via flow cytometry as described 
below. 
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DNA Damage Induction In Vivo 
 
To explore the in vivo response to DNA damaging agents, rats were given an 
intraperitoneal (ip) injection of 10 or 15mg/kg etoposide. Radiation (2Gy) and DMSO 
treated animals were used as controls. All treatment groups contained quadruplicate 
replicates. Rats were cannulated in jugular vein and blood collection was from cannula. 
Whole blood was collected at 1, 2, 7 and 24 hours post dose and fixed immediately by 
adding 50X volume of Phosflow
TM
 (1X concentration, warmed to 37°C) (BD, Catalog 
Number: 554656).. Samples were inverted 8-10 times to ensure mixing and incubated at 
room temperature for 10 minutes to ensure complete cellular lysis. Tubes were spun at 
200 x g for 10 minutes and supernatant was discarded. 200ul PBS was added to each 
pellet and samples were pipetted up and down to ensure mixing. Samples were 
transferred to a 96-well v-bottom plate and plates were spun at 2000rpm for 5 minutes. 
Supernatant was removed and 200uL ice cold 90% methanol was added and pipetted up 
and down to ensure mixing. Plates were covered with a plate cover and allowed to 
permeabilize overnight at -20°C.  
After permeabilization, samples were pipetted up and down to ensure mixing and 
100ul of each sample was transferred to a new plate and the remaining material was 
stored at -80°C. Plates were spun at 2000rpm for 5 minutes and the supernatant was 
removed. 20ul staining master mix containing 5ul gH2AX antibody (BD Biosciences, 
anti-H2AX (pS139), Alexa Fluor 647, Clone: N1-431, Catalog # 560447), 0.5ul pKAP 
antibody (Pierce, Phospho-TIF1beta, pSer824 Ab DyLight 488, Lot #PL212965), and 
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14.5ul PBS-0.5% BSA was added to each sample and was incubated at room temperature 
for 1 hour, on a plate shaker. 200ul PBS + 0.5% BSA was added to each sample and the 
plates were spun at 2000rpm for 5 minutes. Supernatant was discarded. Samples were 
resuspended in 100ul PBS + 0.5% BSA and evaluated via flow cytometry as described 
below.  
 
Flow Cytometry 
 
 The 96-well plates were loaded onto the BD FACSCalibur™ platform and the 
flow rate was set to 35uL/min. Acquisition was gated based on the lymphocyte 
population and was set to collect data until 1 million events were captured. The number 
of cells positive for both pKAP1 and pH2AX were captured.  
 
Statistical Analyses 
 
For the hair follicle and flow cytometry assays, all data were plotted using 
Microsoft Excel 2011 (Microsoft). Data from these two assays were normalized to 
vehicle controls and two-tailed T tests were performed to determine whether DNA 
damage marker (e.g. gH2AX, pChk1, pKAP1) expression significantly differed between 
donors and treatment groups.  
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A statistical analysis of pChk1 labeling from the 24-hour experiment was 
performed using a linear random effects model to try to understand, from the observed 
variability, how many hairs would need to be analyzed to see a statistically significant 
change in pChk1 expression.  
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Chapter III 
Results 
 
This study demonstrates that human hair follicles are a viable option for 
biomarker monitoring in oncology. Specifically, gH2AX can be used as a DNA damage 
marker. However, the number of hair follicles collected must be carefully considered 
before incorporating this collection into clinical studies due to the variability in this 
sample type.  Results from this study also indicate that human whole blood will need 
more investigation before it is used clinically. Detection in whole blood was unsuccessful 
after ex vivo stimulation but in vivo exploration in rats yielded positive data indicating 
that there may be a disconnect between the ability to fully detect damage induction in ex 
vivo and in vivo experiments.   
 
Evaluation of DNA Damage in Formalin Fixed Paraffin Embedded Hair Follicles via 
Immunohistochemistry 
 
In order to evaluate DNA damage response in hair follicles, hairs were plucked 
from volunteer subjects in accordance with the protocol.  Plucked follicles were treated 
with three DNA damaging agents: carboplatin, etoposide, and irinotecan. Hair follicles 
were then formalin fixed and paraffin embedded in preparation for assessment of DNA 
damage markers by immunohistochemistry (IHC). Hair follicles sectioned for IHC 
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evaluation were incubated with anti-γ-H2AX antibody at a range of dilutions from 1:50 
to 1:500 in TBST containing 5% normal goat serum in order to optimize labeling. 
Following primary antibody incubation, samples were incubated with biotinylated goat-
anti-rabbit IgG (Vector BA-1000) at 1:200 for 30 minutes at room temperature.  After 
evaluation of the range of primary antibody concentrations, the 1:250 dilution was chosen 
as optimal. This staining protocol was utilized throughout the rest of the study. Figure 1 
below illustrates a representative hair follicle stained with anti-γ-H2AX antibody at 1:250 
dilution after treatment with etoposide.  
 
Figure 1.  gH2AX labeling following etoposide treatment. Image taken using 10X 
objective. Brown = DAB 
 
 Similarly, hair follicles sectioned for IHC evaluation were incubated with anti-
pChk1 (Ser345) antibody at a range of dilutions - 1:50, 1:100, 1:200, 1:500 and 1:1000 in 
TBST containing 5% normal goat serum in order to optimize labeling. Following primary 
antibody incubation, samples were incubated with biotinylated goat-anti-rabbit IgG 
(Vector BA-1000) at 1:200 for 30 minutes at room temperature.  After evaluation of the 
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range of primary antibody concentrations, the 1:50 dilution was chosen as optimal. This 
staining protocol was utilized throughout the rest of the study. Figure 2 below illustrates a 
representative hair follicle stained with anti-pChk1(ser345) antibody at 1:50 dilution after 
treatment with carboplatin.  
 
Figure 2.  pChk1 labeling following etoposide treatment. Image taken using 10X 
objective. Brown = DAB 
 
DNA Damage Induction in Response to Carboplatin or Etoposide in Hair Follicles as 
Measured by γ-H2AX and pChk1 
 
 To assess the variability in γ-H2AX and pChk1 induction, mean scores for 
cumulative total percent positive cells were calculated for both γ-H2AX and pChk1 after 
treatment with DNA damaging agents. Standard deviation was determined using the total 
percent positive scores between hairs within a group. Donor 1 demonstrated an increase 
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in the percent positive nuclei for γ-H2AX across all three test items when compared to 
DMSO alone. Two tailed Student’s T-tests applied to the data showed that the induction 
of γ-H2AX after treatment with 10µM etoposide was significant (p=0.006) compared to 
the DMSO control group. Conversely, despite the increases in γ-H2AX staining with 
50µM carboplatin and 100nM SN38, both were found to be insignificant (p=0.078 and 
p=0.419, respectively). Results are presented in Figure 3. 
 Donor 2 showed only a slight increase in the number of labeled cells when 
cultured ex vivo. Only treatment with etoposide induced a significant increase in the 
number of positively labeled nuclei for γ-H2AX compared to DMSO control (p=2.9x10-
5
). While ex vivo treatment with carboplatin induced an increase in γ-H2AX positive 
nuclei, the induction was not statistically significant when compared to DMSO control 
(p=0.15). Conversely, treatment with SN38 resulted in a decrease in γ-H2AX expression, 
however this was insignificant (p=0.12). Results are presented in Figure 3. 
 Carboplatin, etoposide and SN38 all showed increased expression of γ-H2AX in 
comparison to DMSO in Donor 3. A two-tailed T-test proved the increase due to 
treatment with both carboplatin and etoposide was statistically significant when 
compared to DMSO controls (p=0.03 and 0.0014, respectively). One of the three donor 3 
hair follicles sectioned and stained after treatment with etoposide was excluded from 
analyses due to poor quality. The change in labeling expression for SN38 was not 
significant (p=0.10). Results are presented in Figure 3. 
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Figure 3.  Expression of gH2AX after 24 hours of ex vivo treatment with DNA damaging 
agents. Percent positive cells for gH2AX after treatment with carboplatin, etoposide and 
SN38 normalized to DMSO control. * denotes significance (two-tailed T-test against 
equivalent donor vehicle; p<0.05) 
  
Overall, the variability in gH2AX induction between hair follicles from a single 
donor was high across all donors.  Further, all DNA damaging agents lead to an increase 
in damage as measured by gH2AX with etoposide yielding the most robust and consistent 
response across all three donors.  
In donor 1, all three DNA damaging agents resulted in an increase in the 
percentage nuclei positively labeled for pChk1 compared to DMSO. However the only 
significant increase in pChk1 labeling compared to DMSO was after ex vivo treatment 
* 
* 
* 
* 
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with etoposide (p=-0.02). Treatment with carboplatin and SN38 resulted in non-
significant increases in pChk1 (p=0.37, p=0.12, respectively). Results are presented in 
Figure 4. 
 In donor 2, treatment with carboplatin resulted in a slight increase when compared 
to vehicle, with much larger inductions in pChk1 labeling seen after treatment with both 
etoposide and SN38. Treatment with etoposide was the only agent to induce a statistically 
significant increase in pChk1 expression (p=0.03). Treatment with carboplatin and SN38 
resulted in insignificant changes in pChk1 (p>0.05). Results are presented in Figure 4. 
 Donor 3 showed much lower pChk1 labeling than donors 1 and 2 but 
demonstrated small increases in pChk1 expression following exposure to DNA damaging 
items (all insignificant). Results are presented in Figure 4.  
 35 
  
Figure 4.  Expression of pChk1 after ex vivo treatment with DNA damaging agents. 
Percent positive cells for pChk1 after treatment with carboplatin, etoposide and SN38 
normalized to DMSO control. * denotes significance (two-tailed T-test against equivalent 
donor vehicle; p<0.05) 
 
Overall, the variability between hair follicles from a single donor was high across 
all donors and DNA damaging agents, but the trend (increased DNA damage) was 
consistent across the group of three donors. Given the expected variability, more hair 
follicles from individual donors may be required to drive a more accurate assessment of 
pChk1 induction. Also of note, the total number of cells staining positive for pChk1 was 
extremely low with treatment with etoposide yielding the most robust response in DNA 
damage, as measured by pChk1 with a maximum percent induction < 1.5% total cells.    
 
* 
* 
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Dynamics of DNA damage induction in response to Carboplatin in Hair Follicles 
 
 Compared to DMSO treatment alone, carboplatin culture increased gH2AX 
labeling across all Donor 1 time-points from between a 1.9 fold increase at 24 hours to a 
3.8 fold increase at 28 hours. However, two-tailed Student’s T-tests applied to the data 
found that only the increase after 28 hours was significantly different compared to the 
time matched DMSO control group (p=0.007). The results are summarized in Appendix 1 
as Figure 7. 
 The response to DNA damaging agent, carboplatin, was not significant in Donor 
2. The percentage of cells positive for gH2AX was actually decreased in Donor 2 after 
treatment with carboplatin for 17 hours. Treatment with carboplatin for 24 and 28 hours 
resulted in an extremely small and non-significant fold increase in gH2AX. The results 
are summarized in Appendix 1 as Figure 7. 
 Labeling was significantly increased in Donor 3 with carboplatin treatment across 
all timepoints ranging from a 4.8 fold increase at 17 hours to a 12.5 fold increase at 24 
hours compared to time matched DMSO treated controls. All changes in the percentage 
of cells that stained positive for gH2AX after treatment with carboplatin for 17, 24, and 
28 hours were significant (p=0.008, 0.0009, 0.0006 respectively). The results are 
summarized in Appendix 1 as Figure 7. 
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The non-robust and variable changes in gH2AX staining after treatment with 
carboplatin in Donors 1 and 2 followed by the significant induction in gH2AX staining at 
all timepoints in Donor 3 not only speaks to the high level of variability between hair 
follicles from a single donor, but the high variability in response between donors.  
  
Evaluation of Carboplatin-induced DNA Damage in Hair Follicles by pChk1 at Multiple 
Timepoints 
 
 All compound treatments failed to induce any significant changes in labeling 
levels at any timepoint. There was a large amount of variability between hair follicles 
from the same donor. In addition, the number of positively labeled cells was low in all 
culture groups across all timepoints. Furthermore, the labeling that was determined as 
positive was so slight that it was difficult to detect any meaningful response when 
considering the variability between hair follicles. The results are summarized in 
Appendix 2 as Figure 8. 
 
Data for Donor 3 at 17 and 24 hours was excluded due to the fact that the 
immunohistochemistry run was an outlier and produced slightly more intense nuclear 
staining when compared to other immunohistochemistry runs. To ascertain whether the 
data from this run should be included or excluded from statistical analyses, Dixon’s Q 
test for outliers was completed on the treatment group means across all three donors and 
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found statistically that the affected samples should be removed (rejecting the null 
hypothesis that the outlier should be preserved, p>0.05).  
 
Effect of Ex Vivo Treatment on DNA Damage Induction in Hair Follicles 
 
 Ex vivo culture of the hair follicles was shown to affect gH2AX labeling. The 
data is summarized in Appendix 3 as Figure 9 and illustrates that maintenance in media 
alone was sufficient to affect gH2AX labeling. In hairs from donor 1, a decrease in total 
labeling, compared to freshly plucked, was observed when hairs were maintained ex 
vivo. Two-tailed Student’s T-tests applied to the untreated culture (media alone) group 
found that the reduction in labeling from fresh was significant only after 28 hours of 
culture (p=0.007). Comparison of the 0.1% DMSO vehicle with the media control group 
showed further reductions across all timepoints where only the reduction in labeling due 
to the addition of DMSO to the culture media at 17 hours was statistically significant 
(p=0.032). Results are illustrated in Appendix 3 as Figure 9. 
 These findings were also seen in donor 3 where cultured hairs revealed a 
statistically significant reduction in labeling across all DMSO treated groups when 
compared to hairs cultured in media alone. The reduction in gH2AX labeling at the 17 
and 28-hour timepoints were statistically significant (p=0.02, 0.023, respectively). 
Differences seen between fresh hairs fixed immediately and the hairs cultured in media 
alone were not significant. Results are illustrated in Appendix 3 as Figure 9. Thus, the 
media and DMSO treatment may cause down-regulation of the damage signal, indicating 
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that we may be missing something in the ex vivo setting where we have to culture the 
hairs in DMSO.  
 In contrast to donors 1 and 3, there was an increase in gH2AX labeling when hairs 
were placed into culture media and a further increase in gH2AX labeling with the 
inclusion of DMSO alone into the media. Cultured and fresh hairs, however, from donor 
2 displayed much lower levels of gH2AX labeling compared to donor 1 and 3. Analysis 
of the data proved all changes in total labeling as result of culture or DMSO to be 
insignificant. Results are illustrated in Appendix 3 as Figure 9. 
 
 In hairs from donors 2 and 3 a significant decrease in pChk1 labeling was 
observed compared to freshly plucked samples when hairs were maintained ex vivo 
(untreated) across all culture timepoints. However, though significant, this statistically 
significant result only constitutes a very small reduction from 2.1% to 1.48% to below 
1% across all timepoints for donors 2 and 3 respectively. Additionally, the number of 
positively labeled cells was low in all culture groups. Results are illustrated in Appendix 
4 as Figure 10. 
In the analysis of both gH2AX and pChk1, expression of DNA damage markers at 
baseline (fresh, fixed immediately) was variable. Similarly, follicle-to-follicle variability 
within a treatment group was high. This makes determining a response to stimuli (ie. ex 
vivo treatment with carboplatin) difficult.  
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DNA Damage Induction in Whole Blood as Measured by gH2AX and pKAP1 Double 
Positive Cells 
 
 In examining the induction in DNA damage in whole blood, results indicate that 
the ex vivo stimulation with DNA damaging agents lead to minimal enhancement of 
DNA damage. Specifically, after ex vivo stimulation with carboplatin, etoposide, and 
irinotecan there was minimal non-significant induction in DNA damage markers pKAP1 
and gH2AX using any of the DNA damaging agents. The human whole blood was treated 
with 2 Gy of radiation as a positive control as it has been shown to successfully induce 
damage ex vivo. Results from the samples treated with radiation indicate that the staining 
and evaluation via flow cytometry was successful. Maximum DNA damage was seen 1 
hour post radiation, and was almost 100% resolved by 8 hours post treatment. Results are 
illustrated in Figure 5 below.  
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Figure 5.  Ex vivo induction in DNA damage by DNA damaging agents not successful in 
whole blood as measured by damage markers, pKAP1 and gH2AX. Radiation 
successfully induced DNA damage with maximum damage seen at 1-hour post treatment. 
 
Individual data points for each of the DNA and positive control listed below with 
standard deviations generated by pooling the duplicate replicates and three individual 
donors.  
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Table 4.  Percent double positive lymphocytes for pKAP1, gH2AX (standard deviation). 
 IR (2 Gy) DMSO Carboplatin SN38 Etoposide 
1 hour 94.9 (2.04) 0.04 (0.29) 0.46 (0.48) 0.10 (0.09) 0.24 (0.22) 
4 hour 63.1 (5.94) 0.15 (0.12) 0.15 (0.18) 0.24 (0.16) 0.18 (0.09) 
8 hour 10.2 (3.11) 0.22 (0.11) 0.30 (0.11) 0.23 (0.14) 0.25 (0.10) 
 
 
Results indicate that ex vivo induction in DNA damage using chemotherapeutic agents 
was unsuccessful at all timepoints as measured by damage markers, pKAP1 and gH2AX. 
However, ex vivo treatment of whole blood with 2 Gy radiation successfully induced 
damage at all timepoints with maximum damage observed 1 hour after treatment.  
 
In vivo DNA Damage Response after Treatment with Etoposide in Rats 
 
 After the ex vivo treatment with DNA damaging agents in human whole blood 
was shown to be unsuccessful, DNA damage response was explored in vivo. Specifically, 
rats were treated with two doses of etoposide and blood was collected at 1, 2, 7 and 24 
hours post treatment. Data from individual animals in each of the treatment groups (n=4) 
was pooled. Results indicate that DNA damage was successfully induced and a 
measurable increase compared to DMSO was detected at 1 and 2 hours post dose in the 
10mg/kg dose and at all timepoints in the 15mg/kg dose. However, increases 1 hour post 
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the 10mg/kg dose (p=0.019) and at 1 and 2 hours post the 15mg/kg dose (p=0.004 and 
0.022, respectively) were the only statistically significant results. Full results are 
illustrated in Figure 6 below.  
The in vivo DNA damage induction occurred in a dose-dependent fashion in rats 
treated with etoposide. Specifically, the 15mg/kg dose induced a higher level of DNA 
damage as measured by lymphocytes positive for both pKAP1 and gH2AX than the 
10mg/kg dose at all timepoints. However the only timepoint that showed a statistically 
significant difference between the two doses was the 1-hour timepoint (p=0.0007). 
Results are illustrated in Figure 6 below. The ability to induce a DNA damage response 
in vivo in rats highlights the difference between the ex vivo and in vivo etoposide 
treatments and indicates that blood may be a viable surrogate to tumor tissue when 
monitoring DNA damage biomarkers.  
 44 
 
Figure 6.  Treatment with etoposide significantly induces DNA damage response in 
whole blood in rats compared to DMSO control. *indicates statistical significance p<0.05 
using Student’s t-test.  
 
 A group of animals (n=4) was also treated with 2 Gy of radiation as a positive 
control. Animals treated with 2 Gy radiation had 99.0% of lymphocytes positive for 
gH2AX and pKAP1 at 1 hour (data not shown). 
 
 
* 
* 
* 
* 
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Chapter IV 
Discussion 
 
 
  Our results indicate that both hair follicles and whole blood may be suitable 
tissue types for biomarker monitoring of the mechanistic effects of DNA damaging 
agents in oncology trials. With that in mind, we observed quite a bit of variability in both 
tissue types in ex vivo specimens and less variability in vivo. These data indicate that 
optimization and validation of specific biomarkers after treatment with chemotherapeutic 
agents may need to be done using hair and blood from in vivo experiments given the 
potential limitations of ex vivo material, especially in blood.  With proper in vivo 
validation, assessment of on-mechanism biomarkers in blood and hair may be used in 
dose and schedule selection in future generations of DNA damaging agents.  
 
Biomarker Monitoring in Hair Follicles 
 
 This thesis has confirmed that hair follicles can be used for on mechanism 
biomarker monitoring in response to DNA damaging agents. Hair follicles can be used 
for biomarker monitoring in response to DNA damaging agents. We observed that up to 
70% of cells stained positive for gH2AX after treatment with the DNA damaging agent 
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etoposide. However, the DNA damage induction seen by measuring pChk1 staining after 
treatment with DNA damaging agents was markedly less when compared to gH2AX 
staining. The maximum induction in DNA damage was less than 2% after treatment with 
Irinotecan (SN38) when using pChk1 as a marker of DNA damage. This could be due to 
the fact that H2AX is not only phosphorylated at Ser139 in response to DNA damaging 
agents, gH2AX can also be generated during DNA replication, as a consequence of 
apoptosis or in response to residual DNA damage. H2AX is recruited directly to the 
damaged DNA and is phosphorylated to activate the DNA damage response (DDR) by 
multiple DDR pathways including homologous recombination (HR) and base excision 
repair (BER) pathways. Conversely, Chk1 is activated mainly by ataxia telangiectasia 
and Rad3-related protein (ATR) through phosphorylation after ATR is activated in 
response to DNA damage. Thus, as pChk1 is slightly downstream of the DNA damage 
response, lessening its expression in response to DNA damage compared to H2AX, it 
explains some of the differences between the degree of activation of pChk1 and the 
degree of activation of H2AX.  
 Additionally, phosphorylation of Chk1 may be more transient when compared to 
H2AX and is specific to the S-phase of the cell cycle where as the activation of H2AX 
can occur in all phases of the cell cycle. Thus, the DNA damage induction could be very 
strong, but the timepoints in which we were monitoring pChk1 may not have captured the 
maximum induction. Future studies could explore a more granular time course to pin 
point maximum induction of pChk1 in response to DNA damaging agents.  
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DNA Damage Induction in Hair is Variable by Agent and Donor 
 
 Our results indicate that measurement of gH2AX can be used as an on mechanism 
biomarker of DNA damage to carboplatin, etoposide, and irinotecan.  Although the three 
DNA damaging agents tested did not induce the same levels of DNA damage, damage 
induction was detectable in response to all agents tested. Across all three donors, 
etoposide induced the greatest DNA damage as measured by gH2AX. Treatment with 
etoposide had about a two-fold greater induction in DNA damage compared to 
carboplatin and irinotecan in the same donors. This data suggests that treatment of 
surrogate tissues with a topoisomerase II inhibitor that causes direct double strand breaks 
may be a more potent inducer of damage response in surrogate tissues.  
 The variability in damage between agents might further be attributed to the 
concentrations used during culture. For each of the three agents, the IC90 concentration 
in cancer cell lines was used. Perhaps the IC90 concentrations in cell lines did not 
translate exactly to hair follicles. The only way to know if the concentrations of 
carboplatin and irinotecan were low is to do a full dose titration to understand the 
dose/response relationship.   
 Treatment with carboplatin also resulted in the induction in DNA damage in hair 
follicle. Here we saw a significant increase in the DNA damage marker, gH2AX, in one 
donor after 24 hours of ex vivo treatment with carboplatin. As a result, we decided to 
explore multiple timepoints to understand if treatment for 24 hours resulted in the 
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maximum response or if we were missing the window of highest induction. Hairs were 
treated, ex vivo, with carboplatin for 17, 24, and 28 hours. Results indicated that 28 hours 
was the timepoint in which we saw the most robust and consistent induction across all 
three donors. Thus, while it seems from this experiment that 28 hours is best, additional 
work to evaluate other timepoints would be useful before using these assays in the clinic.  
Finally, treatment with irinotecan (active agent, SN38), a topoisomerase I 
inhibitor, did not result in a statistically significant inductions in DNA damage response 
as measured by gH2AX or pChk1. Topoisomerase I is responsible for relaxation of DNA 
supercoils by making single and double stranded cuts in the DNA, crossing the stands 
through one another then, resealing the breaks. Inhibition of topoisomerase I leads to the 
inhibition of DNA replication and transcription. Perhaps the difference in MOA explains 
the differences in the amount of damage observed.  
There was significant variability between donors as well. One of the donors did 
not show a significant induction in gH2AX at any of the timepoints. Furthermore, the 
level of induction in one of the donors that showed a statistically significant induction in 
gH2AX at 28 hours was almost 40% higher than the other donor that the other 
statistically significant increase at 28 hours.   
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Effect of Ex Vivo Culture on Hair Follicles 
 
 In this thesis, DNA damage response was evaluated in an ex vivo environment. 
However, in the clinic, patients would typically be treated intravenously with DNA 
damaging agents, and the hair follicles would be exposed to the agents in vivo due the 
vascularization of the scalp. To more fully understand the utility of hair follicles as a 
surrogate tissue to assess DNA damage response, in vivo studies in patients or rodents 
should be performed. However, in our experiments, the hair follicles were plucked from 
healthy volunteers, placed in an ex vivo culture containing cell culture media 
supplemented with the DNA damaging agent. Hair follicles collected in the clinic would 
not be exposed to DMSO and the body would be metabolizing the DNA agent such that 
the concentration of the agent would not be constant. In addition, the body would 
maintain the hair follicles and vascularization of the scalp would keep the epithelial cells 
alive. Thus, we examined the effect the ex vivo culture itself had on the hair follicles.  
 We observed that maintenance in media alone was sufficient to induce gH2AX 
labeling. Thus, there was some level of cell death occurring just because the hair follicles 
were being maintained outside of the body. Whether the increase is due to donor 
responses to plucking trauma, in intrinsic donor-specific characteristic, or as a result of 
prolonged culture is unknown. However, when comparing the level of DNA damage in 
vehicle treated hair follicles compared to untreated follicles in media alone, the hairs 
treated with DMSO showed increased damage compared to media. Thus, the addition of 
 50 
vehicle alone was enough to elicit a response in DNA damage compared to the culture 
itself.  
 These effects due to the ex vivo culture were variable by donor. In donor 1, 
untreated hair follicles maintained in media and DMSO treated follicles resulted in 
decreased gH2AX when compared to hair follicles plucked and fixed immediately. In 
comparison, donor 2 showed an increase in gH2AX in hair follicles maintained ex vivo 
(untreated and DMSO treated).  
 Lastly, though we saw a statistically significant reduction in pChk1 in untreated 
hair follicles, the number of cells that were positive for pChk1 to begin with, in the 
freshly plucked hair follicles, was extremely low. In the two donors that demonstrated a 
statistically significant reduction, the number of cells positive for pChk1 was reduced 
from about 1.5 to 2% of cells to only about 0.5% in both donors. Thus, even though the 
results are statistically significant, the percent reductions are extremely low and the 
significance is not replicated in the DMSO treated group.  
 
Biomarker Monitoring in Blood 
 
 Here we demonstrate minimal DNA damage induction in ex vivo treated blood 
and a robust induction in vivo after treatment with etoposide. Thus, results from whole 
blood experiments demonstrate discordance between ex vivo treated whole blood and 
whole blood taken and processed from mouse experiments.  Given the discordance 
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between experiments and the fact that the ex vivo experiments failed to definitively prove 
that whole blood can be used as a surrogate tissue type for biomarker monitoring in the 
clinic, additional in vivo experiments are suggested prior to clinical use. Human whole 
blood from three healthy donors was treated with carboplatin, etoposide, and irinotecan 
for 1, 4, and 8 hours. Blood was also collected and treated with 2 Gy radiation and fixed 
after 1, 4, and 8 hours as a positive control. Channels on the flow cytometer were gated to 
identify cells that were double positive for gH2AX and pKAP1. Samples treated with the 
various DNA damaging agents showed no increase in DNA damage response (DDR) 
markers compared to DMSO. Therefore, human whole blood treated ex vivo with three 
DNA damaging agents failed to induce a DNA damage response (DDR) as measured by 
DDR biomarkers, gH2AX and pKAP1. This could be due, in part, to the fact that the 
blood was removed from the in vivo environment and is not undergoing DNA replication. 
Since these three DNA damaging agents work to inhibit DNA replication and 
transcription, treating whole blood in an ex vivo manner where the cells are not cycling 
would not result in a robust response in DDR markers. In addition, there is a significant 
gap between the time in which the blood is removed from the volunteer and the time it is 
treated with the DNA damaging agent. During this time, the blood is sitting at the bench 
at room temperature, which may affect the integrity of the blood components, adversely 
effecting the results.  
 In order to understand the effect ex vivo stimulation had on the results, the 
experiment was repeated in vivo in rats. Rats were treated with intraperitoneal (ip) 
etoposide or 2 Gy IR as a positive control. In vivo treatment with etoposide resulted in a 
 52 
dose-dependent DDR where the higher dose of etoposide resulted in maximum damage at 
1 hour post treatment. Specifically, treatment with etoposide resulted in about a 4-fold 
induction in DDR markers, gH2AX and pKAP1, compared to DMSO.  By the 24-hour 
timepoint, the compound had been fully metabolized by the rats, thus resulting in the 
lowest DDR. A key difference between the in vivo and ex vivo experiments is that 
compound is maintained at a constant concentration in the ex vivo experiment. In 
contrast, in vivo experiments more closely mimic human conditions where drug is 
metabolized over time allowing one to understand the relationship between drug 
exposure and biomarker response.  
Taken together, these results indicate that DNA damage response can be 
monitored in whole blood. However, optimization and validation in an ex vivo setting 
may not possible using chemotherapeutics that target DNA replication since whole blood 
is not undergoing DNA replication ex vivo. Radiation, however, can be used in ex vivo 
experiments, as it does not rely on the cell cycle to induce DNA damage.  Specifically, 
radiation causes both single and double strand breaks in the DNA leading to genomic 
instability. Thus, radiation can be modeled in ex vivo experiments for clinical readiness 
where targeted agents may be combined with radiation for example. 
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Implications and Future Experiments 
 
 With a recent emphasis on molecularly targeted therapies oftentimes in 
combination with chemotherapeutic agents, biomarkers that are indicative of a drugs 
pharmacodynamic mechanism of action or illustrative of target engagement are essential. 
Biomarker monitoring in the target tumor tissue is not always possible, lending itself to 
the importance of finding surrogate tissues. Confirmation that both hair follicles and 
blood can be used to monitor “on-mechanism” changes induced by DNA damaging 
agents in a clinical oncology trial has large implications for the development of novel 
biomarkers. If surrogate tissues can be utilized in the clinic instead of tumor tissue 
biopsies, this will allow for the collection of more data at more timepoints with a 
decrease in patient burden.   
 One limitation of this thesis is the level of DNA damage induction in hair follicles 
seen with the chemotherapeutics tested. Examination of hair follicles in vivo in rodents or 
in humans may result in a better fold induction because the hairs are being maintained by 
the animal’s vascular system instead of by cell culture media ex vivo. In addition, 
exploring more concentrations and timepoints to try to identify maximum induction may 
help to reduce variability. Additionally, other surrogate tissues could be explored in 
addition to hair follicles and blood. Skin, for example, could be a viable option for 
biomarker monitoring that is easily accessible and amenable to repeat sampling when 
compared to tumor tissue biopsies.  
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In conclusion, both hair follicles and whole blood are viable options for 
biomarker monitoring in the clinic and may serve as an alternative to a very burdensome 
procedure, the standard tumor tissue biopsy.  
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Chapter V 
Appendices 
 
Appendix 1. Treatment with Carboplatin Induced DNA Damage as Measured by gH2AX 
 
a.) 
 
b.)  
 
 
* 
* 
 56 
c.)  
 
Figure 7.  Treatment with Carboplatin induced DNA damage as measured by gH2AX. 
Percentage of Carboplatin-treated hair follicle cells positively stained for gH2AX, 
relative to DMSO treated controls. DNA damage induction at 17h (a), 24h (b), and 28h 
(c) after treatment with 50uM Carboplatin. * denotes significance (two tailed T-test 
against equivalent donor vehicle; p<0.05) 
 
* 
* 
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Appendix 2. Treatment with Carboplatin Induced DNA Damage as Measured by pChk1 
 
a.) 
 
b.) 
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c.) 
 
Figure 8.  Treatment with Carboplatin induced DNA damage as measured by pChk1. 
Percentage of Carboplatin-treated hair follicle cells positively stained for pChk1, relative 
to DMSO treated controls. DNA damage induction at 17h (a), 24h (b), and 28h (c) after 
treatment with 50uM Carboplatin. * denotes significance (two tailed T-test against 
equivalent donor vehicle; p<0.05) 
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Appendix 3. Baseline DNA Damage During Ex Vivo Culture as Measured by gH2AX 
 
a.) 
 
 
b.) 
 
* * 
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c.) 
 
Figure 9.  Baseline DNA damage during ex vivo culture as measured by gH2AX. DNA 
damage induction in donor 1 (a), donor 2 (b), and donor 3 (c) after culture with either 
media alone or media supplemented with 0.1% DMSO. * denotes significance (two tailed 
T-test equivalent against fresh hairs fixed immediately (media alone group) or media 
alone group (0.1% DMSO group).  
 
* 
* 
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Appendix 4. Baseline DNA damage during Ex Vivo Culture as Measured by pChk1 
 
a.) 
 
b.) 
 
* * 
* 
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c.) 
 
Figure 10.  Baseline DNA damage during ex vivo culture as measured by pChk1. DNA 
damage induction in donor 1 (a), donor 2 (b), and donor 3 (c) after culture with either 
media alone or media supplemented with 0.1% DMSO. * denotes significance (two tailed 
T-test equivalent against fresh hairs fixed immediately (media alone group) or media 
alone group (0.1% DMSO group). 
* 
* 
* 
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